Early Administration of Botox® in Neuropathic Pain Due to Thoracoscopy or Thoracotomy
Status:
Withdrawn
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
Botulinum toxin type A has been reported to inhibit the release of various pain
neurotransmitters (SP, CGRP, glutamate) responsible for neurogenic inflammation, a process
that results from the sensitization of C-fiber nociceptors (peripheral sensitization). This
action is probably responsible for the analgesic effect of botulinum toxin type A recently
demonstrated in patients with neuropathic pain of peripheral origin.In those studies,
patients had been suffering for years. The investigators can hypothesizes that earlier
administration of Botox in the course of neuropathic pain might prevent central
sensitization, that is secondary to peripheral sensitization. The investigators can hope to
increase efficacy of Botulinum toxin type A injections and to prevent chronification of pain.
Phase:
Phase 3
Details
Lead Sponsor:
University Hospital, Limoges
Treatments:
abobotulinumtoxinA Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA